Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer
Part of Cancer, Digestive system clinical trials.
The PRELUDE Study: A Prospective Cohort Study Comparing Neoadjuvant Radiotherapy Followed by Total Mesorectal Excision Versus Upfront Surgery in Patients with Locally Advanced Proximal Rectal Cancer The PRELUDE Study is a single-center, prospective cohort study designed to compare neoadjuvant radiotherapy followed by total mesorectal excision (TME) with upfront surgery alone in patients with locally advanced proximal rectal cancer. The primary endpoint is the rate of local recurrence. Secondary endpoints include overall survival, disease-free survival, and functional outcomes related to bowel, urinary, and sexual function. The aim of this study is to determine whether neoadjuvant radiotherapy reduces the risk of local recurrence and improves long-term oncological and functional outcomes in this anatomically distinct subgroup of patients with rectal cancer.
Summary from the official registry record.
Who can take part
- Locally Advanced Proximally Rectal Cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying different treatments for patients with early-stage rectal cancer that has a higher chance of coming back after local removal. It looks at whether adding radiation or chemoradiation after local surgery can improve outcomes.
This trial tests giving targeted radiation, chemotherapy, and immunotherapy before surgery to shrink locally advanced rectal cancer. It aims to improve treatment results for patients whose tumors have not spread but are at high risk of coming back.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial tests a personalized approach to treating rectal cancer before surgery. Doctors will adjust radiation therapy during treatment based on how well your tumor is shrinking, combined with chemotherapy drugs to improve outcomes.
This study tests a specific “before surgery” treatment (radiation plus chemotherapy), followed by more chemotherapy to improve outcomes in people with certain types of rectal cancer. You might be considered if your cancer is locally advanced but not spread to distant organs.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.